Shanghai Kanda Bio-Technology

Shanghai Kanda Bio-Technology is a clinical-stage biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company leverages its proprietary K-mRNA platform and advanced lipid nanoparticle (LNP) delivery systems to address significant unmet needs in infectious diseases and oncology. Its lead candidate, KD-001, is an mRNA vaccine for COVID-19 that has progressed into Phase 2 clinical trials. Kanda Bio maintains a full-stack capability ranging from mRNA sequence design to large-scale GMP manufacturing at its facility in Shanghai. The company is positioned as a key innovator in the Chinese mRNA landscape, with a pipeline that includes vaccines for rabies, shingles, and influenza.